fluticasone and Cat-Diseases

fluticasone has been researched along with Cat-Diseases* in 8 studies

Trials

2 trial(s) available for fluticasone and Cat-Diseases

ArticleYear
Treatment of naturally occurring asthma with inhaled fluticasone or oral prednisolone: A randomized pilot trial.
    Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2021, Volume: 85, Issue:1

    The objective of this study was to compare inhaled glucocorticoids with oral glucocorticoids for treatment of naturally occurring feline asthma. Secondary goals were to evaluate serum allergy testing results in cats and to quantify the effect of an inhaled glucocorticoid (fluticasone) on glucose homeostasis. Nine cats with asthma were enrolled on the basis of clinical signs, thoracic radiographic findings, and airway eosinophilia. Cats were randomized and 4 cats were treated with oral glucocorticoids and 5 cats with inhaled glucocorticoids, with a 7-day course of oral glucocorticoids overlapping at the start of therapy. Cats were evaluated at baseline and at 8 wk with thoracic radiographs, bronchoalveolar lavage, lung function testing, and fructosamine levels. Serum allergen panels were evaluated. All cats were clinically normal after treatment and had significantly improved airway eosinophilia and decreased nucleated cell count. No improvement was seen in radiographic changes after treatment with either therapy. Oral, but not inhaled glucocorticoids, caused a decrease in airway resistance, although cats in the inhaled group had a higher baseline resistance than those in the oral group. Fructosamine levels did not change with treatment. Fifty percent of cats tested positive for immunoglobulin E (IgE) antibodies. Asthma is a heterogeneous condition; individual cats responded well to both oral and inhaled glucocorticoids. Ongoing evaluation of the potential underlying causes and therapeutic options is warranted with a larger group of cats.. L’objectif de l’étude était de comparer le traitement de l’asthme félin avec des glucocorticoïdes inhalés et administrés par voie entérale. Les objectifs secondaires étaient d’évaluer les résultats de tests d’allergies de chats atteints d’asthme félin et de quantifier l’effet d’un glucocorticoïde inhalé (fluticasone) sur l’homéostasie du glucose. Neuf chats atteints d’asthme félin ont été recrutés selon les signes cliniques, les trouvailles radiographiques et les évaluations cytologiques des voies aériennes (éosinophilie). Les chats ont été randomisés. Quatre chats ont été traités avec des glucocorticoïdes par voie entérale et cinq chats avec des glucocorticoïdes inhalés dont les 7 premiers jours ont été associés à l’administration de glucocorticoïdes par voie orale. Les chats ont initialement été évalués au moment du recrutement et puis à huit semaines avec des radiographies thoraciques, lavage bronchoalvéolaire, tests de fonction pulmonaire et dosage de la fructosamine. Des tests sériques d’allergènes ont également été évalués. Tous les chats ont eu une résolution des signes cliniques après le traitement et avaient une amélioration significative du compte éosinophilique du LBA. Aucune amélioration des lésions radiographiques suivant le traitement soit inhalé ou entéral n’a été observée. Seuls les glucocorticoïdes entéraux ont causés une diminution de la résistance des voies respiratoires. Toutefois les chats du groupe de traitement de glucocorticoïdes inhalés avaient, avant l’initiation du traitement, une résistance pulmonaire plus importante. Les niveaux de fructosamine n’ont pas changé significativement, et ce dans les deux groupes de traitement. 50 % des chats ont testé positif pour des anticorps IgE contre des allergènes inhalés communs. L’asthme est une entité clinique hétérogène; les chats ont individuellement bien répondu autant au traitement inhalé qu’au traitement entéral. L’étude des potentielles causes sous-jacente et des différentes options thérapeutiques sont recommandées dans une population plus grande de chats.(Traduit par les auteurs).

    Topics: Administration, Inhalation; Administration, Oral; Animals; Asthma; Cat Diseases; Cats; Female; Fluticasone; Male; Pilot Projects; Prednisolone

2021
Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model.
    Veterinary journal (London, England : 1997), 2012, Volume: 192, Issue:1

    The objective of this study was to investigate whether high-dose inhaled fluticasone propionate (FP), alone or in combination with salmeterol (SAL), is as effective as oral prednisolone in reducing airway inflammation and obstruction in cats with experimentally-induced acute asthma. Six cats sensitised to Ascaris suum (AS) were enrolled in a prospective controlled therapeutic trial and underwent four aerosol challenges, at 1-month intervals with AS allergen. The allergen - stimulated animals received four consecutive days treatment with either oral prednisolone at 1mg/kg twice daily, 500 μg of FP inhaled twice daily, or a combination of FP/SAL at 500 μg/50 μg inhaled twice daily, respectively, according to a randomised cross-over design. Treatment-related changes in lung function, airway responsiveness (AR) and bronchoalveolar lavage fluid (BALF) cytology were assessed. Barometric whole-body plethysmography (BWBP) was used for the assessment of respiratory variables and AR. No significant differences in respiratory rate or Penh (an estimate of airflow limitation measured by BWBP) were detected among treatment groups. Allergen-induced airway hyper-responsiveness was significantly inhibited by all three steroid treatments (P<0.05). The mean BALF eosinophil percentage (±SEM) was lower after oral and inhaled corticosteroid treatment and these changes were significant for groups receiving prednisolone and the FP/SAL combination. Findings suggest high-dose FP, particularly in combination with SAL, is effective in ameliorating airway inflammation and hyper-responsiveness in this model of acute feline asthma, and highlight the potential use of these drugs in cats experiencing acute exacerbations of the naturally occurring disease.

    Topics: Administration, Inhalation; Administration, Oral; Albuterol; Allergens; Androstadienes; Animals; Anti-Inflammatory Agents; Antigens, Helminth; Ascaris suum; Asthma; Bronchodilator Agents; Cat Diseases; Cats; Cross-Over Studies; Drug Combinations; Female; Fluticasone; Fluticasone-Salmeterol Drug Combination; Male; Prednisolone; Prospective Studies

2012

Other Studies

6 other study(ies) available for fluticasone and Cat-Diseases

ArticleYear
Integrated basic lung and heart ultrasound with X-ray (TUSX) for the diagnosis of asthma, chronic bronchitis and laryngeal paralysis, and treatment with inhaled fluticasone using home-made mask in dogs and cats.
    Polish journal of veterinary sciences, 2022, Volume: 25, Issue:2

    Basic lung and heart ultrasound examination combined with chest X-ray (TUSX) is currently considered to be very useful for differentiation of asthma, chronic bronchitis and laryngeal paralysis from other diseases with dyspnea/coughing. Among 252 client-owned animals with persistent dyspnea/cough/noisy breathing, in 197 of them: pulmonary edema, pneumonia, lung cancer, free pleural fluid, pneumothorax, lung contusion or heart disease were diagnosed. The remaining 55 animals (42 dogs and 13 cats) were diagnosed with asthma (in 13 cats), chronic bronchitis (in 37 dogs) and laryngeal paralysis (in 5 dogs) using TUSX. These animals were qualified for inhaled fluticasone treatment using 3 types of spacers - two commercial and a home- -made mask. 36 animals (65.5%) completed the trail. In 26 of them (72.2%) the owners observed complete, long lasting relief of the symptoms, and the owners of 7 animals (19.5%) declared a considerable clinical improvement, regardless of the type of spacer used. The owners of 3 animals (8.3%) did not see any improvement. The proposed diagnostic and therapeutic management improved long-term clinical status of the vast majority (91.7%) of animals. Therefore, it seems justified to include the TUSX diagnostic protocol in daily veterinary practice and to encourage owners to prepare home-made face masks for inhaled fluticasone treatment.

    Topics: Animals; Asthma; Bronchitis, Chronic; Cat Diseases; Cats; Dog Diseases; Dogs; Dyspnea; Fluticasone; Lung; Vocal Cord Paralysis; X-Rays

2022
What Is Your Diagnosis? Inflammatory granuloma.
    Journal of the American Veterinary Medical Association, 2016, May-01, Volume: 248, Issue:9

    Topics: Animals; Anorexia; Anti-Inflammatory Agents; Antinematodal Agents; Cat Diseases; Cats; Diagnosis, Differential; Dyspnea; Endoscopy; Female; Fenbendazole; Fluticasone; Granuloma, Respiratory Tract; Heart Murmurs; Lethargy; Male; Prednisolone; Radiography, Thoracic; Respiratory Sounds; Tachypnea; Trachea; Tracheal Diseases; Tracheal Neoplasms

2016
Functional phenotype and its correlation with therapeutic response and inflammatory type of bronchoalveolar lavage fluid in feline lower airway disease.
    Journal of veterinary internal medicine, 2015, Volume: 29, Issue:1

    Currently, functional assessment to monitor therapeutic response in feline lower airway disease (FLAD) has limited application.. To evaluate if expiratory indices derived from pseudo-tidal breathing flow-volume loop (pTBFVL) representing lower airway obstruction would decrease after clinical improvement and to investigate the correlation between functional phenotype and inflammatory cell type in bronchoalveolar lavage (BAL) fluid.. Nineteen client-owned cats with FLAD.. Prospective observational study. Functional assessment with pTBFVL indices (eg, peak to mid-expiratory flow; PEF/EF50) and conventional barometric whole body plethysmography (BWBP) parameters (eg, enhanced pause) was carried out before receiving treatment. BAL was performed to analyze inflammatory cell types. Signs were assessed by scoring. The cats were treated with glucocorticoids daily and functional testing was repeated.. Loop indices PEF/EF50 and PEF/EF25 were significantly decreased after treatment (P < .001). Conventional BWBP parameters were not significantly different before and after treatment. Cats with PEF/EF50 > 1.51 before treatment had a significantly higher granulocyte (eosinophil plus neutrophil) percentage in BAL fluid (P = .014). Granulocyte percentage in BAL fluid was strongly correlated with PEF/EF25 (P = .001, rs = 0.74) and moderately correlated with PEF/EF50 (P = .022, rs = 0.57), whereas eosinophil or neutrophil percentage alone had no significant correlation with functional parameters.. Functional parameters including PEF/EF50 and PEF/EF25 can be used for monitoring therapeutic response. The presence of airflow limitation during mid- to late expiration is affected by the overall extent of granulocyte infiltration.

    Topics: Androstadienes; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cat Diseases; Cats; Fluticasone; Inflammation; Lung Diseases; Prednisolone; Respiratory Therapy

2015
Localized demodicosis due to Demodex cati on the muzzle of two cats treated with inhalant glucocorticoids.
    Veterinary dermatology, 2014, Volume: 25, Issue:3

    Feline demodicosis due to Demodex cati is a rare skin disease often associated with concurrent disease and generalized immunosuppression. Local immunosuppression due to the application of topical immunomodulatory drugs, such as glucocorticoids and tacrolimus, or by tumour cells has been suggested as a potential trigger for development of localized demodicosis in humans and animals.. The goal was to describe two cats with asthma that developed localized demodicosis on the muzzle as a result of chronic therapy with a glucocorticoid administered via dispensing inhaler mask.. In both cats, the muzzle area exposed to the fluticasone-dispensing chamber exhibited patchy alopecia, mild erythema, crusting and scaling. Deep skin scraping revealed D. cati. Discontinuation or reduction of fluticasone and administration of milbemycin resulted in resolution of clinical signs within 2 months in both cats. A negative skin scrape was obtained after 7 months of milbemycin in one of the cats.. Demodicosis should be considered as a possible differential diagnosis in cats with primary alopecia or other skin lesions on the face exposed to inhalant glucocorticoids. Minimization of contact between the inhalant glucocorticoid and the skin can be achieved by wiping residual powder from the face and by keeping the mask tightly pressed to the skin to avoid contact with the surrounding area.

    Topics: Aerosols; Androstadienes; Animals; Anthelmintics; Anti-Inflammatory Agents; Asthma; Cat Diseases; Cats; Fluticasone; Macrolides; Male; Mite Infestations; Mites; Nebulizers and Vaporizers; Respiratory Therapy

2014
Effects of fluticasone propionate dosage in an experimental model of feline asthma.
    Journal of feline medicine and surgery, 2010, Volume: 12, Issue:2

    Cats with inflammatory bronchial disease are usually treated with glucocorticoid (GC) drugs to reduce airway inflammation. Inhalant GC delivery can preserve airway effects while systemic effects are minimized. An appropriate dosage regimen for inhaled GC in cats has not been investigated. A blinded, randomized, cross-over study design was used to investigate the ability of three different dosages of the inhalant GC fluticasone propionate delivered by metered dose inhaler to ameliorate eosinophilic airway inflammation in cats with experimentally induced allergic airway inflammation. Further, suppression of the hypothalamic-pituitary-adrenal axis (HPAA) at each dose was assessed. Fluticasone administered at dosages of 44, 110, or 220 microg q 12h reduced airway eosinophilia by 74%, 82%, or 81%, respectively (no difference). None of the dose regimens tested caused HPAA suppression. We conclude that a twice daily dosage of 44 microg fluticasone should be evaluated for the management of cats with naturally occurring inflammatory bronchial disease.

    Topics: Administration, Inhalation; Androstadienes; Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Cat Diseases; Cats; Dose-Response Relationship, Drug; Female; Fluticasone; Hypothalamo-Hypophyseal System; Male; Metered Dose Inhalers; Pituitary-Adrenal System; Random Allocation; Specific Pathogen-Free Organisms; Treatment Outcome

2010
Inhaled fluticasone reduces bronchial responsiveness and airway inflammation in cats with mild chronic bronchitis.
    Journal of feline medicine and surgery, 2006, Volume: 8, Issue:1

    This study investigated the effect of inhaled fluticasone on lower airway inflammation and bronchial responsiveness (BR) to inhaled carbachol in cats with very mild, chronic bronchitis (n = 5) that were compared with healthy cats serving as controls (n = 6). Chest radiographs, BR tests performed non-invasively by barometric whole body plethysmography (BWBP) and bronchoalveolar lavage (BAL) were performed before and after treatment. BR was quantified by calculating the concentration of carbachol inducing bronchoconstriction (C-Penh300%), defined as a 300% increase of baseline Penh, an index of bronchoconstriction obtained by BWBP. BAL fluid was analyzed cytologically and the oxidant marker 8-iso-PGF2alpha was determined. At test 1, healthy cats and cats with bronchitis were untreated, whereas for test 2 inhalant fluticasone (250 microg once daily) was administrated for 2 consecutive weeks to cats with bronchitis. Control cats remained untreated. Inhaled fluticasone induced a significant increase in C-Penh300% and a significant decrease of BAL fluid total cells, macrophages, neutrophils and 8-iso-PGF2alpha in cats with bronchitis, whilst untreated control cats did not show significant changes over time. This study shows that a 2-week fluticasone treatment significantly reduced lower airway inflammation in very mild bronchitis. BR could be successfully monitored in cats using BWPB and decreased significantly in response to inhaled fluticasone. 8-Iso-PGF2alpha in BAL fluid was responsive to treatment and appeared as a sensitive biomarker of lower airway inflammation in cats.

    Topics: Administration, Inhalation; Androstadienes; Animals; Anti-Inflammatory Agents; Bronchitis, Chronic; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Case-Control Studies; Cat Diseases; Cats; Female; Fluticasone; Male; Plethysmography; Treatment Outcome

2006